Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review-Reference-Cited by-同舟云学术

Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review

Published:2017-09 Issue: Volume:59 Page:71-78
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Queirolo Paola,Spagnolo Francesco

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference51 articles.

1. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin. Cancer Res,2009

2. The PRISMA group. preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement;Moher;PLoS Med,2009

3. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. [updated March 2011] The Cochrane Collaboration; 2011.

4. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab;Topalian;J Clin Oncol,2014

5. Nivolumab plus Ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-19

2. Symptomatic pseudoprogression in metastatic colorectal cancer;BMJ Case Reports;2024-06

3. Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study;Frontiers in Oncology;2024-05-31

4. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18

5. Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post‐marketing surveillance;The Journal of Dermatology;2024-03-03